| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Liminatus Pharma, Inc.$0.12
+0.01 (+7.21%)
Market Cap
7.60 M
EPS
-0.40
P/E Ratio
-
Value Trade
1.35 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
400.00 K
Operating CF
-2.02 M
Total Assets
2.79 M
Total Liabilities
2.92 M
Equity
-132.60 K
D/E Ratio
12,345
-5.89 %
Week
-15.55 %
1 Month
-25.7 %
3 Month
-80.24 %
6 Month
-98.39 %
5 Year
-98.39 %
All Time
Cash Data
Cash Position
1.91 M
Monthly Burn
672.00 K
Runway
1.9 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
1.20 M
52 Week Range
0.13 - 33.66
% held by Insiders
47.93 %
% held by Institutions
3.29 %
Enterprise Value
7.14 M
Total Shares
44.90 M
Short %
5.26 %
Float Shares
33.49 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LIMN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Liminatus Pharma, Inc. (LIMN) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
LIMN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIMN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIMN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
LIMN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
LIMN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LIMNLiminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds
Liminatus Pharma has entered into a warrant exercise agreement, raising $1.9 million from existing investors. The agreement involves the exercise of 10,344,000 shares of common stock and the issuance of new warrants for 20,688,000 shares. The new warrants have an exercise price of $0.18 and require stockholder approval before they can be exercised.
Read more →LIMNLiminatus Pharma Announces Nasdaq Delisting Notification
Liminatus Pharma has received a delisting notification from Nasdaq due to failure to meet market value requirements. The company was given a grace period to regain compliance but did not succeed. Unless an appeal is filed by May 27, 2026, trading of its securities will be suspended on May 29, 2026. The company intends to appeal the decision.
Read more →LIMNLiminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline
Liminatus Pharma has announced a merger with InnocsAI to enhance its oncology cell therapy pipeline. The merger will involve the acquisition of multiple biologic and cellular therapy assets aimed at addressing challenges in hematologic cancers and solid tumors. The transaction is valued at approximately $320 million and is expected to provide development opportunities across various cancer indications.
Read more →LIMNLiminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Liminatus Pharma, Inc. announced the pricing of a public offering of 13,813,000 shares at $0.29 each, aiming to raise $4.0 million. The offering includes warrants for additional shares, potentially raising $6.0 million. The funds will support working capital and business objectives. The closing is expected on February 18, 2026.
Read more →Competitive Position
How LIMN ranks across every disease it competes inCompetitive Position is a premium feature
See how LIMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial